Hodgkin's Lymphoma - evaluation of patients submitted to Autologous transplantation of hematopoietic cells in the Hematology Service of the Hospital Walter Cantídio - Fortaleza, Brazil

The Autologous HSCT is an important alternative for refractory or recurrent HL patients in terms of survival and improved quality of life. This study analyzes the results of autologous BMT performed in HL patients in the Transplant Unit of the HUWC/ HEMOCE (Fortaleza - CE, Brazil). Fifty-two transpl...

Full description

Saved in:

Bibliographic Details
Published in:	Revista da Associacao Medica Brasileira (1992) Vol. 62 Suppl 1; no. suppl 1; pp. 34 - 38
Main Authors:	Duarte, Fernando Barroso, Fernandes, Mabel Gomes de Brito, Kaufmann, Jacques, Barroso, Karine Sampaio Nunes, Leitão, João Paulo de Vasconcelos, Araujo, Beatriz Stela Gomes de Souza Pitombeira, Costa, Clara Maria Bastos Eloy da, Quixadá-Medica, Acy Teles, Holanda, Jacqueline de Souza, Landim, Samuel Vasconcelos, Pitombeira, Maria Helena
Format:	Magazine Article
Language:	English
Published:	Brazil 01-10-2016
Subjects:	Adolescent Adult Brazil Disease-Free Survival Female Hematopoietic Stem Cell Transplantation - methods Hematopoietic Stem Cell Transplantation - mortality Hodgkin Disease - mortality Hodgkin Disease - surgery Humans Male Middle Aged Time Factors Transplantation Conditioning - methods Transplantation, Autologous - methods Treatment Outcome Young Adult
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The Autologous HSCT is an important alternative for refractory or recurrent HL patients in terms of survival and improved quality of life. This study analyzes the results of autologous BMT performed in HL patients in the Transplant Unit of the HUWC/ HEMOCE (Fortaleza - CE, Brazil). Fifty-two transplanted patients were studied from January 2009 to October 2015, among them, 30 men and 22 women, mean age of 28.2 years. All of them received GCS-F during the mobilization, in some cases associated with Vinorelbine or Plerixafor, with CD34 collection averaging 4.8 CD34/kg. The conditioning was performed with BEAC, NEAM or BEAM and the grafting with an average of 10 days. The evaluation on D + 100 showed: CR - 42 (82.7%), PR - 08 (13.5%) and 02 (3.8%) deaths, three and six days after cell infusion. After the D+100, 08 patients in CR showed HL recurrence from 06 to 36 months; 03 died and 05 are being treated with brentuximab; among the 08 patients in PR, 01 died due to HL activity, 04 months after BMT and 07 patients are undergoing treatment. The final evaluation of HL transplant patients showed an OS of 88.5% and a DFS of 61.5% in 6 years, with OS of the chemosensitive patients of 81% and of the chemoresistant ones, of 72.6%. It is possible to conclude that the Autologous HSCT has shown to be an excellent rescue therapy regarding tolerance, as well as the overall survival.
ISSN:	0104-4230 1806-9282 0104-4230
DOI:	10.1590/1806-9282.62.Suppl1.34